CaNCaP-T
Research type
Research Study
Full title
CaNCaP-T: Cambridge Neoadjuvant Cancer of the Prostate Translational Study
IRAS ID
287622
Contact name
Simon Pacey
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
1 years, 3 months, 18 days
Research summary
As with other solid tumours, early stage (localised) disease can be treated with curative intent, e.g. by surgery or radiotherapy. However, around 33% of men have aggressive disease which will still recur and be fatal with time
Unlike other solid cancer types there has been little impact on overall survival by adding medical therapy to surgery or radiotherapy. Therefore, men who relapse represent an unmet medical need both to better identify those at greatest risk of relapse as well as how to optimize additional therapy, for example addition of appropriate molecularly targeted therapies.
This study looks to analyse samples from two previous window of opportunity clincial trials, CANCAP02 and CANCAP03. In both these clinical trials men with high risk prostate cancer took a short course of novel drug prior to surgery to remove their prostate cancer.
Each individual sample is linked to pseudo-anonymised clinical data which includes patient demographics, tumour characteristics at diagnosis and at surgery and clinical outcomes of toxicity.
Collated together, these samples along with the clinical data could represent a unique resource. In addition we will use matched control tissue from another Cambridge study, DIAMOND, and additional tissue available from the Human Research Tissue Bank in Cambridge.
REC name
North East - Tyne & Wear South Research Ethics Committee
REC reference
20/NE/0240
Date of REC Opinion
8 Oct 2020
REC opinion
Favourable Opinion